: iStockAnalyst.com Symbols Feed

Mentor Capital Top Gainer in Cancer Immunotherapy Index

Fri, 28 Aug 2009 17:53:33 GMT

SAN DIEGO--(BUSINESS WIRE)--The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks increased 23% since its inception July 10, 2009. The CI Index was developed by Mentor Capital as a peer group index against which investors could bench mark stock performance in the rapidly growing immunotherapy sector. In this first reporting, the strong six-week CI Index gain was paced by the 78% share price improvement of Mentor Capital, Inc. (Pink Sheets: MNTR - News).[More...]

FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX

Tue, 23 Jun 2009 00:14:00 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lette (...)[More...]

Oncothyreon (ONTY) Research Note

Wed, 18 Mar 2009 19:01:00 GMT

Oncothyreon: Price: $1.21; Market Cap (MM): $23.6 Market Outperform; Target Price: $4.00 Simos Simeonidis, Ph.D. - Senior Biotech Analyst: Rodman & Renshaw Transferring Coverage. We are assuming coverage of Oncothyreon, a biotechnology company focused (...)[More...]

Oncothyreon Reports Second Quarter 2009 Financial Results

Wed, 12 Aug 2009 20:49:00 GMT

SEATTLE, Aug. 12 /CNW/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008.
The increase in net loss for the three-month period was primarily the result of this non-cash charge and a decrease in revenue described below, partially offset by decreased operating expenses.
The decrease in net loss for the six-month period was primarily the result of the transfer of manufacturing activities for Stimuvax(R) to Merck KGaA in December 2008, which resulted in a decrease of combined research and development and manufacturing expenses partially offset by a decrease in both contract manufacturing and licensing revenue from collaborative agreements and the non-cash charge discussed above.

: iStockAnalyst.com Symbols Feed

Mentor Capital Top Gainer in Cancer Immunotherapy Index

FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX

Oncothyreon (ONTY) Research Note

Oncothyreon Reports Second Quarter 2009 Financial Results

Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter

Mentor Capital Cancer Immunotherapy Index Posts Second 20% Plus Monthly Gain Lead By ImmunoCellular Therapeutics

Oncothyreon to present at BioCentury NewsMakers Conference

Oncothyreon to present at Rodman & Renshaw Global Healthcare Conference

New Cancer Immunotherapy Index Posts 23% Gains Lead By Mentor Capital, Inc. And Oncothyreon

BenchmarkJournal.Com Free Analyst Review for ADSK, SRCL, TFSL, OPWV, TSRA and ONTY

Oncothyreon announces closing of $15.0 million registered direct financing

Oncothyreon announces webcast of second quarter 2009 financial results conference call

Oncothyreon announces commitments to purchase $15.0 million of company securities in a registered direct financing

Stocks to Watch for Tuesday, August 4, 2009: MNGA -- MagneGas Receives Its Most Significant Independent Media Attention to Date in the Form of a Feature Article in Welding Journal!

Form 4 Oncothyreon Inc. For: Dec 03 Filed by: Karan Shashi K. (10K)

Form 4 Oncothyreon Inc. For: Dec 03 Filed by: Christianson Gary (10K)

Form 4 Oncothyreon Inc. For: Dec 03 Filed by: KIRKMAN ROBERT L (10K)

Form 3 WILLIAMS DOUGLAS E For: Oct 01 (10K)

Form 4 Karan Shashi K. For: Aug 18 (10K)

Form 4 Oncothyreon Inc. For: Jun 12 Filed by: HENNEY CHRISTOPHER S (10K)

Form 4 Jackson Richard L. For: Jun 12 (10K)

Form 4 STOUGHTON W VICKERY For: Jun 12 (10K)

Form 4 SPIEGELMAN DANIEL K For: Jun 12 (10K)

Form 4/A SPIEGELMAN DANIEL K For: Mar 11 (10K)